Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP005 Dose-Escalation in Actinic Keratoses
NCT00427050Phase 2Completed
- Sponsor
- Peplin
- Start
- Jan 2007
- Primary completion
- Nov 2007
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ingenol mebutate in actinic keratosis (AK), sponsored by Peplin. Started Jan 2007; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00427050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427050.